

18<sup>th</sup> November 2016

Announcements  
National Stock Exchange of Australia  
PO Box 283  
NEWCASTLE NSW 2300

Market Announcement – Glucose Biosensor Systems (Greater China) and general update

iQN Ltd (NSX:IQN) Would like to announce the following planned tactics as part of the company's ongoing business strategy:

- Salivary Glucose Biosensor Commercialisation:
  - IPO of Glucose Biosensor Systems (Greater China) (GBSGC) on NASDAQ during the first half of 2017. GBGC is a subsidiary of Life Science Biosensor Diagnostics, being a joint venture company co-owned with iQX Limited.
  - The objective of the listing, will be to fund the prelaunch and launch strategy of the Glucose Biosensor into the Greater China market. The blood glucose monitoring market in Greater China is estimated to be at US\$4b annually.
- IQN's planned migration to the ASX is nearing the final stages of completion. The prospectus is planned to be lodged with ASIC late 2016 / early 2017. A timetable will be released to the markets as soon as it is finalized.
- IQN's planned cross listing on NASDAQ, is expected to follow the IQN ASX listing.

Accordingly, IQN requests the removal of the previously requested trading halt.

For and on behalf of the Board.



G Incollingo  
Company Secretary  
iQnovate Ltd

For further information, please contact:

**Media**

Marketing, Media & Communications  
[Email: info@theiqgroup.com.au](mailto:info@theiqgroup.com.au)  
Phone: +61 2 8239 5400

Australia • Phone: +61 2 8239 5400

Sydney: Level 7, 222 Clarence Street, Sydney, NSW 2000,

New York: 400 Madison Avenue, Suite 10A, New York City NY10017 USA | +1 212 433 2630

London: 20 Broadwick Street, London, W1F-8HT, UK • Phone: +44(0)2077121508

Shanghai: Level 31, Jin Mao Tower, 88 Shiji Avenue, Pudong, Shanghai, 200120, China | +86 21 2890 9033

## Safe Harbor Statement

Any statements in this announcement that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

## SOURCE IQnovate Ltd

IQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, iQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

iQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.